Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323353620> ?p ?o ?g. }
- W4323353620 endingPage "153" @default.
- W4323353620 startingPage "148" @default.
- W4323353620 abstract "Purpose Lymphovascular space invasion (LVSI) predicts for higher rates of recurrence and increased mortality in endometrial cancer. Using 3-tier LVSI scoring, a PORTEC-1 and -2 trials analysis demonstrated that substantial LVSI was associated with worse locoregional (LR-DFS) and distant metastasis disease-free survival (DM-DFS), and these patients possibly benefited from external beam radiation therapy (EBRT). Furthermore, LVSI is a predictor for lymph node (LN) involvement, but the significance of substantial LVSI is unknown in patients with a pathologically negative LN assessment. We aimed to evaluate clinical outcomes of these patients in relation to the 3-tier LVSI scoring system. Methods and Materials We performed a single-institutional retrospective review of patients with stage I endometrioid-type endometrial cancer who underwent surgical staging with pathologically negative LN evaluation from 2017 to 2019 with 3-tier LVSI scoring (none, focal, or substantial). Clinical outcomes (LR-DFS, DM-DFS, and overall survival) were analyzed using the Kaplan-Meier method. Results A total of 335 patients with pathologically LN-negative stage I endometrioid-type endometrial carcinoma were identified. Substantial LVSI was present in 17.6% of patients; 39.7% of patients received adjuvant vaginal brachytherapy and 6.9% of patients received EBRT. Adjuvant radiation treatment varied by LVSI status. In patients with focal LVSI, 81.0% received vaginal brachytherapy. Among patients with substantial LVSI, 57.9% received vaginal brachytherapy alone, and 31.6% of patients received EBRT. The 2-year LR-DFS rates were 92.5%, 98.0%, and 91.4% for no LVSI, focal LVSI, and substantial LVSI, respectively. The 2-year DM-DFS rates were 95.5%, 93.3%, and 93.8% for no LVSI, focal LVSI, and substantial LVSI, respectively. Conclusions In our institutional study, patients with pathologically LN-negative stage I endometrial cancer with substantial LVSI had similar rates of LR-DFS and DM-DFS compared with patients with none or focal LVSI. These findings highlight the need for multi-institutional studies to validate the prognostic value of substantial LVSI in this patient population. Lymphovascular space invasion (LVSI) predicts for higher rates of recurrence and increased mortality in endometrial cancer. Using 3-tier LVSI scoring, a PORTEC-1 and -2 trials analysis demonstrated that substantial LVSI was associated with worse locoregional (LR-DFS) and distant metastasis disease-free survival (DM-DFS), and these patients possibly benefited from external beam radiation therapy (EBRT). Furthermore, LVSI is a predictor for lymph node (LN) involvement, but the significance of substantial LVSI is unknown in patients with a pathologically negative LN assessment. We aimed to evaluate clinical outcomes of these patients in relation to the 3-tier LVSI scoring system. We performed a single-institutional retrospective review of patients with stage I endometrioid-type endometrial cancer who underwent surgical staging with pathologically negative LN evaluation from 2017 to 2019 with 3-tier LVSI scoring (none, focal, or substantial). Clinical outcomes (LR-DFS, DM-DFS, and overall survival) were analyzed using the Kaplan-Meier method. A total of 335 patients with pathologically LN-negative stage I endometrioid-type endometrial carcinoma were identified. Substantial LVSI was present in 17.6% of patients; 39.7% of patients received adjuvant vaginal brachytherapy and 6.9% of patients received EBRT. Adjuvant radiation treatment varied by LVSI status. In patients with focal LVSI, 81.0% received vaginal brachytherapy. Among patients with substantial LVSI, 57.9% received vaginal brachytherapy alone, and 31.6% of patients received EBRT. The 2-year LR-DFS rates were 92.5%, 98.0%, and 91.4% for no LVSI, focal LVSI, and substantial LVSI, respectively. The 2-year DM-DFS rates were 95.5%, 93.3%, and 93.8% for no LVSI, focal LVSI, and substantial LVSI, respectively. In our institutional study, patients with pathologically LN-negative stage I endometrial cancer with substantial LVSI had similar rates of LR-DFS and DM-DFS compared with patients with none or focal LVSI. These findings highlight the need for multi-institutional studies to validate the prognostic value of substantial LVSI in this patient population." @default.
- W4323353620 created "2023-03-08" @default.
- W4323353620 creator A5005998810 @default.
- W4323353620 creator A5023245938 @default.
- W4323353620 creator A5023468026 @default.
- W4323353620 creator A5027078316 @default.
- W4323353620 creator A5030482195 @default.
- W4323353620 creator A5038212601 @default.
- W4323353620 creator A5040538629 @default.
- W4323353620 creator A5045579312 @default.
- W4323353620 creator A5050775851 @default.
- W4323353620 creator A5056022955 @default.
- W4323353620 creator A5059711716 @default.
- W4323353620 creator A5069562305 @default.
- W4323353620 creator A5070555068 @default.
- W4323353620 creator A5072644854 @default.
- W4323353620 creator A5078798271 @default.
- W4323353620 creator A5082714186 @default.
- W4323353620 creator A5082795489 @default.
- W4323353620 date "2023-09-01" @default.
- W4323353620 modified "2023-10-14" @default.
- W4323353620 title "Is Substantial Lymphovascular Space Invasion Prognostic in Patients With Pathologically Lymph Node-Negative Endometrial Cancer?" @default.
- W4323353620 cites W1903539786 @default.
- W4323353620 cites W2069337087 @default.
- W4323353620 cites W2097409147 @default.
- W4323353620 cites W2147101451 @default.
- W4323353620 cites W2583455670 @default.
- W4323353620 cites W2734610904 @default.
- W4323353620 cites W2888567495 @default.
- W4323353620 cites W2897596953 @default.
- W4323353620 cites W3044249289 @default.
- W4323353620 cites W3092284014 @default.
- W4323353620 cites W3122480463 @default.
- W4323353620 cites W3181471292 @default.
- W4323353620 cites W3193307874 @default.
- W4323353620 cites W4206841660 @default.
- W4323353620 cites W4293241248 @default.
- W4323353620 doi "https://doi.org/10.1016/j.ijrobp.2023.02.053" @default.
- W4323353620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36893818" @default.
- W4323353620 hasPublicationYear "2023" @default.
- W4323353620 type Work @default.
- W4323353620 citedByCount "0" @default.
- W4323353620 crossrefType "journal-article" @default.
- W4323353620 hasAuthorship W4323353620A5005998810 @default.
- W4323353620 hasAuthorship W4323353620A5023245938 @default.
- W4323353620 hasAuthorship W4323353620A5023468026 @default.
- W4323353620 hasAuthorship W4323353620A5027078316 @default.
- W4323353620 hasAuthorship W4323353620A5030482195 @default.
- W4323353620 hasAuthorship W4323353620A5038212601 @default.
- W4323353620 hasAuthorship W4323353620A5040538629 @default.
- W4323353620 hasAuthorship W4323353620A5045579312 @default.
- W4323353620 hasAuthorship W4323353620A5050775851 @default.
- W4323353620 hasAuthorship W4323353620A5056022955 @default.
- W4323353620 hasAuthorship W4323353620A5059711716 @default.
- W4323353620 hasAuthorship W4323353620A5069562305 @default.
- W4323353620 hasAuthorship W4323353620A5070555068 @default.
- W4323353620 hasAuthorship W4323353620A5072644854 @default.
- W4323353620 hasAuthorship W4323353620A5078798271 @default.
- W4323353620 hasAuthorship W4323353620A5082714186 @default.
- W4323353620 hasAuthorship W4323353620A5082795489 @default.
- W4323353620 hasConcept C121608353 @default.
- W4323353620 hasConcept C126322002 @default.
- W4323353620 hasConcept C126838900 @default.
- W4323353620 hasConcept C143998085 @default.
- W4323353620 hasConcept C146357865 @default.
- W4323353620 hasConcept C151730666 @default.
- W4323353620 hasConcept C2777088508 @default.
- W4323353620 hasConcept C2777416452 @default.
- W4323353620 hasConcept C2778740770 @default.
- W4323353620 hasConcept C2779013556 @default.
- W4323353620 hasConcept C2780849966 @default.
- W4323353620 hasConcept C509974204 @default.
- W4323353620 hasConcept C71924100 @default.
- W4323353620 hasConcept C86803240 @default.
- W4323353620 hasConceptScore W4323353620C121608353 @default.
- W4323353620 hasConceptScore W4323353620C126322002 @default.
- W4323353620 hasConceptScore W4323353620C126838900 @default.
- W4323353620 hasConceptScore W4323353620C143998085 @default.
- W4323353620 hasConceptScore W4323353620C146357865 @default.
- W4323353620 hasConceptScore W4323353620C151730666 @default.
- W4323353620 hasConceptScore W4323353620C2777088508 @default.
- W4323353620 hasConceptScore W4323353620C2777416452 @default.
- W4323353620 hasConceptScore W4323353620C2778740770 @default.
- W4323353620 hasConceptScore W4323353620C2779013556 @default.
- W4323353620 hasConceptScore W4323353620C2780849966 @default.
- W4323353620 hasConceptScore W4323353620C509974204 @default.
- W4323353620 hasConceptScore W4323353620C71924100 @default.
- W4323353620 hasConceptScore W4323353620C86803240 @default.
- W4323353620 hasIssue "1" @default.
- W4323353620 hasLocation W43233536201 @default.
- W4323353620 hasLocation W43233536202 @default.
- W4323353620 hasOpenAccess W4323353620 @default.
- W4323353620 hasPrimaryLocation W43233536201 @default.
- W4323353620 hasRelatedWork W2011848842 @default.
- W4323353620 hasRelatedWork W2053104579 @default.
- W4323353620 hasRelatedWork W2079856228 @default.
- W4323353620 hasRelatedWork W2486140844 @default.
- W4323353620 hasRelatedWork W2801199293 @default.